Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.51 |
| ▸ | RARB | P10826 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077835 | 0.85 | PLA2G2A (0.80) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL10830829 | 0.85 | PLA2G2A (0.86) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL10068773 | 0.85 | MAPT (0.47) | PLA2G2A | |
| SCHEMBL28627609 | 0.84 | PLA2G2A (0.77) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL14986138 | 0.84 | PLA2G2A (0.49) | PLA2G2ATP53TSHRPLA2G4BKMT2A | |
| SCHEMBL16247012 | 0.84 | SMN1; SMN2 (0.51) | PLA2G2ATSHR | |
| SCHEMBL5883712 | 0.84 | AHR (0.53) | PLA2G2ATSHR | |
| SCHEMBL557574 | 0.82 | PLA2G2A (0.54) | PLA2G2ATP53TSHRPLA2G4BKMT2A | |
| SCHEMBL11503562 | 0.81 | CNR1 (0.48) | PLA2G2AKMT2A | |
| SCHEMBL27893360 | 0.81 | PLA2G2A (0.63) | PLA2G2ATP53TSHRPLA2G4BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | PLA2G2A 993/4885TP53 4727/4885TSHR 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.